leon-nanodrugs GmbH (“LEON”), a leading nanotechnology activator for the pharmaceutical industry, today announced the appointment of Dr. Hans Frickel as CEO, effective July 1, 2023.
Dr. Hans Frickel, a trained pharmacist and industry manager, has more than 20 years of experience in strategic and operational leadership roles across the pharmaceuticals and medical devices value chain. Prior to joining LEON, he was Managing Director at R‑Biopharm and held several senior operational management roles at BioNTech, Evonik, Midas Pharma, Procter & Gamble and Merck.
Dr Hubert Birner, Chair of the LEON Board of Trustees, said: “On behalf of the Board of Trustees, I am pleased to welcome Dr. Hans Frickel at LEON. With his extensive expertise in various areas of modern drug manufacturing, including manufacturing and QC management, as well as a strong track record in strategy and governance, he is the perfect fit to take LEON to the next stage. On behalf of the Supervisory Board, I would also like to thank our CEO and interim CFO Christian Nafe, our CSO Dr. Setu Kasera and their team for their excellent work in pushing our technology towards commercialization and for the great progress that has been made to date .”
“I am excited to join LEON as we work to transform nanomedicine manufacturing,” says Dr. Hans Frickel, CEO of LEON. “I am impressed by the team’s knowledge and dedication in working to create added value throughout the nano-formulation processing chain. I truly believe that LEON’s NANO devices will significantly enhance the development and manufacturing for today’s and future personalized cell & gene therapies in CDMO, biotechnology, and pharmaceutical companies.”